31680194|t|Bexarotene Attenuates Focal Cerebral Ischemia-Reperfusion Injury via the Suppression of JNK/Caspase-3 Signaling Pathway.
31680194|a|Apolipoprotein E (APOE) is implicated not only in chronic degenerative neurological diseases, such as Alzheimer's disease, but also in acute brain disorders, including traumatic brain injury. Bexarotene, a selective agonist of the retinoid X receptor, has been reported to enhance markedly the expression of APOE. Previous studies have indicated that bexarotene exerts neuroprotective effects in animal models of ischemic stroke by modulating the peripheral immune response and autophagy. However, the role of this drug in neuronal apoptosis and the potential mechanisms involved have yet to be elucidated. The present study employed transient middle cerebral artery occlusion (t-MCAO) as a model of acute cerebral ischemia/reperfusion injury. The experiments were performed in wild-type C57BL/6 mice and APOE gene knockout (APOE-KO) mice. After t-MCAO, mice received intraperitoneal injection of bexarotene (5 mg/kg) or an equal volume of the vehicle. The outcome measurements included neurological deficits, learning ability, spatial memory, infarct volume, histopathology, magnitude of apoptosis, and the level of expression of proteins of the JNK/caspase-3 signaling pathway. The obtained results demonstrated that bexarotene administration significantly improved neurological function, learning ability, and spatial memory in C57BL/6 mice, but not in APOE-KO mice. Infarct volume, tissue damage, neuronal apoptosis rate, and the expression of proteins involved in the JNK/caspase-3 signaling pathway were markedly increased after t-MCAO in both C57BL/6 and APOE-KO mice. Importantly, bexarotene treatment significantly ameliorated all these changes in C57BL/6, but not in APOE-KO mice. In conclusion, bexarotene markedly alleviates the neurological deficits, improves the histological outcome, and inhibits cell apoptosis in mice after t-MCAO. This effect is mediated, at least in part, by up-regulation of APOE. Thus, bexarotene may be a candidate drug for the treatment of cerebral ischemia patients.
31680194	0	10	Bexarotene	Chemical	MESH:D000077610
31680194	28	64	Cerebral Ischemia-Reperfusion Injury	Disease	MESH:D015427
31680194	88	91	JNK	Gene	26419
31680194	92	101	Caspase-3	Gene	12367
31680194	121	137	Apolipoprotein E	Gene	11816
31680194	179	213	degenerative neurological diseases	Disease	MESH:D019636
31680194	223	242	Alzheimer's disease	Disease	MESH:D000544
31680194	256	261	acute	Disease	MESH:D000208
31680194	262	277	brain disorders	Disease	MESH:D001927
31680194	289	311	traumatic brain injury	Disease	MESH:D000070642
31680194	313	323	Bexarotene	Chemical	MESH:D000077610
31680194	472	482	bexarotene	Chemical	MESH:D000077610
31680194	534	549	ischemic stroke	Disease	MESH:D002544
31680194	644	662	neuronal apoptosis	Disease	MESH:D065703
31680194	765	797	middle cerebral artery occlusion	Disease	MESH:D020244
31680194	801	805	MCAO	Disease	
31680194	821	826	acute	Disease	MESH:D000208
31680194	827	863	cerebral ischemia/reperfusion injury	Disease	MESH:D015427
31680194	909	916	C57BL/6	CellLine	CVCL:C0MU
31680194	917	921	mice	Species	10090
31680194	955	959	mice	Species	10090
31680194	969	973	MCAO	Disease	
31680194	975	979	mice	Species	10090
31680194	1018	1028	bexarotene	Chemical	MESH:D000077610
31680194	1108	1129	neurological deficits	Disease	MESH:D009461
31680194	1165	1172	infarct	Disease	MESH:D007238
31680194	1268	1271	JNK	Gene	26419
31680194	1272	1281	caspase-3	Gene	12367
31680194	1340	1350	bexarotene	Chemical	MESH:D000077610
31680194	1452	1459	C57BL/6	CellLine	CVCL:C0MU
31680194	1460	1464	mice	Species	10090
31680194	1485	1489	mice	Species	10090
31680194	1491	1498	Infarct	Disease	MESH:D007238
31680194	1522	1540	neuronal apoptosis	Disease	MESH:D065703
31680194	1594	1597	JNK	Gene	26419
31680194	1598	1607	caspase-3	Gene	12367
31680194	1658	1662	MCAO	Disease	
31680194	1671	1678	C57BL/6	CellLine	CVCL:C0MU
31680194	1691	1695	mice	Species	10090
31680194	1710	1720	bexarotene	Chemical	MESH:D000077610
31680194	1778	1785	C57BL/6	CellLine	CVCL:C0MU
31680194	1806	1810	mice	Species	10090
31680194	1827	1837	bexarotene	Chemical	MESH:D000077610
31680194	1862	1883	neurological deficits	Disease	MESH:D009461
31680194	1951	1955	mice	Species	10090
31680194	1964	1968	MCAO	Disease	
31680194	2045	2055	bexarotene	Chemical	MESH:D000077610
31680194	2101	2118	cerebral ischemia	Disease	MESH:D002545
31680194	2119	2127	patients	Species	9606
31680194	Association	MESH:D015427	12367
31680194	Negative_Correlation	MESH:D000077610	12367
31680194	Negative_Correlation	MESH:D000077610	MESH:D002545
31680194	Association	MESH:D015427	26419
31680194	Negative_Correlation	MESH:D000077610	26419
31680194	Association	MESH:D000544	11816
31680194	Association	MESH:D019636	11816
31680194	Negative_Correlation	MESH:D000077610	MESH:D009461
31680194	Association	MESH:D001927	11816
31680194	Negative_Correlation	MESH:D000077610	MESH:D002544
31680194	Negative_Correlation	MESH:D000077610	MESH:D015427
31680194	Association	12367	26419
31680194	Positive_Correlation	MESH:D000077610	MESH:D007238
31680194	Association	MESH:D000070642	11816
31680194	Association	MESH:D065703	12367
31680194	Positive_Correlation	MESH:D000077610	MESH:D065703

